Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics - ARIA

Study identifier:D3250C00040

ClinicalTrials.gov identifier:NCT02821416

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Double-Blind, Randomized, Parallel Group, Placebo-Controlled Multi-Centre Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics

Medical condition

asthma

Phase

Phase 3

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

46

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 11 Oct 2016
Primary Completion Date: 22 Oct 2019
Study Completion Date: 22 Oct 2019

Study design

Allocation: Randomized
Endpoint Classification: Efficacy
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Dec 2020 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria